 Bedakwaleen is now considered a first-line medicine for treating rife and piston-resistant tuberculosis, RRTB, and can be safely administered over long periods of time. However, it is important to closely monitor the QTCF interval, which may become prolonged due to Bedakwaleen administration. This article was authored by Dismitri Jerkin, Elmira Gerbanova, Jonathan R. Campbell and others.